Precigen, Inc. Common Stock PGEN
Analyst Ratings
- Consensus
- Buy — 2 Buy · 0 Hold · 0 Sell (2 analysts)
- Avg. Price Target
- $14.50 (+86.4% upside)
Key Stats
- Today's Range
- $7.70 – $8.04
- 50-Day Range
- $4.81 – $8.04
- 52-Week Range
- $2.62 – $8.04
- Volume
- 9.58 million shs
- Average Volume
- 4.87 million shs
- Market Cap
- $2.79 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 63.92
- Price / Sales
- 32.50
Short Interest
- Short Interest
- 9.35%
- Days to Cover
- 37.16
Financials (TTM)
- Revenue
- $85.72 million
- Net Income
- $-157,705,000
- Net Margin
- -183.98%
- Return on Equity
- -361.91%
- Debt-to-Equity
- 2.15
About Precigen, Inc. Common Stock
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Related Stocks
Compare head-to-head: PGEN vs LLY·PGEN vs JNJ·PGEN vs ABBV·PGEN vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.